Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Helen Spotswood"'
Autor:
Maria C. Cid, Daniel Engelbert Blockmans, Bhaskar Dasgupta, Sebastian Unizony, Juergen Rech, Elisabeth Brouwer, Carlo Salvarani, Min Bao, Robert Spiera, Martin Aringer, John H. Stone, Helen Spotswood
Publikováno v:
Rheumatology, 61(7), 2915-2922. Oxford University Press
Objective Tocilizumab plus prednisone induces sustained glucocorticoid-free remission in patients with GCA. However, its long-term benefits in new-onset vs relapsing disease are uncertain, and the value of weekly vs every-other-week dosing has not be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56150b0dcb6e306a885b365f12415db9
https://lirias.kuleuven.be/handle/123456789/684567
https://lirias.kuleuven.be/handle/123456789/684567
Autor:
Lorenzo Del Sorbo, Atul Malhotra, Larry Tsai, Helen Spotswood, Ronaldo C. Go, Ivan O. Rosas, Taryn Youngstein, Norbert Bräu, Andrew Ustianowski, Sanjay Bhagani, Min Bao, Sophie Dimonaco, Mariam Aziz, Nichola Cooper, Bradley D Hunter, David J. De La Zerda, Michael F. Waters, Daniel Skiest, Emily Graham, Sinisa Savic, Antonio Cubillo Gracian, Balpreet Matharu, Ivor S. Douglas
Publikováno v:
The New England journal of medicine, vol 384, iss 16
Background Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b63ca1c20584d448f33fd98ff7b410f
https://escholarship.org/uc/item/36k8m3wp
https://escholarship.org/uc/item/36k8m3wp
Autor:
Michael F. Waters, Lorenzo Del Sorbo, Daniel J. Skiest, Sinisa Savic, Antonio Cubillo Gracian, Bradley D. Hunter, Helen Spotswood, Andrew Ustianowski, Min Bao, Ivan O. Rosas, Larry Tsai, Mariam Aziz, Ivor S. Douglas, Nichola Cooper, Sophie Dimonaco, Norbert Bräu, Balpreet Matharu, Sanjay Bhagani, David J. De La Zerda, Ronaldo C. Go, Atul Malhotra, Emily Graham, Taryn Youngstein
BACKGROUNDCOVID-19 is associated with immune dysregulation and hyperinflammation. Tocilizumab is an anti–interleukin-6 receptor antibody.METHODSPatients hospitalized with severe COVID-19 pneumonia receiving standard care were randomized (2:1) to do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59799bab21f5339258434cebbc658983
https://doi.org/10.1101/2020.08.27.20183442
https://doi.org/10.1101/2020.08.27.20183442
Autor:
Ulf Müller-Ladner, Tracy M. Frech, Murray Baron, Jeffrey Siegel, Daniel E. Furst, Angelika Jahreis, Yannick Allanore, Laura Burke, Gerhard Fierlbeck, Christopher P. Denton, Dinesh Khanna, Janet E. Pope, Helen Spotswood, Gabriela Riemekasten, Virginia D. Steen, Lorinda Chung, Marina E Anderson, Santhanam Lakshminarayanan, Celia J. F. Lin, Jacob M van Laar
Publikováno v:
Annals of the Rheumatic Diseases
ANNALS OF THE RHEUMATIC DISEASES
ANNALS OF THE RHEUMATIC DISEASES
ObjectivesAssess the efficacy and safety of tocilizumab in patients with systemic sclerosis (SSc) in a phase II study.MethodsPatients with SSc were treated for 48 weeks in an open-label extension phase of the faSScinate study with weekly 162 mg subcu
Autor:
Marco Matucci-Cerinic, Celia J. F. Lin, Dinesh Khanna, Yannick Allanore, Mette Mogensen, Angelika Jahreis, Gabriela Riemekasten, Marzena Olesińska, Jonathan G. Goldin, Carmen-Marina Mihai, Christopher P. Denton, Maria José Santos, Oliver Distler, Daniel E. Furst, Masataka Kuwana, Dušanka Martinović Kaliterna, Patricia Carreira, Grace Kim, Anastas Batalov, Helen Spotswood, Tatiana Sofía Rodriguez-Reyne, Jeffrey Siegel, Irena Butrimiene, Janet E. Pope, Jacob M van Laar
Publikováno v:
ILD/DPLD of known origin.
Background: Anti–interleukin-6 receptor antibody TCZ showed clinically relevant lung function preservation (forced vital capacity [FVC]) in SSc patients (pts) in a phase 2 trial. Objective: Investigate TCZ vs placebo (PBO) in SSc in a phase 3 trial
Autor:
Helen Spotswood, Jeffrey Siegel, Janet E. Pope, G. Kim, Christopher P. Denton, Marco Matucci-Cerinic, Carina Mihai, T.S. Rodriguez-Reyna, Anastas Batalov, J.M. van Laar, Maria José Santos, Marzena Olesińska, Patricia Carreira, Masataka Kuwana, Mette Mogensen, Angelika Jahreis, Irena Butrimiene, Yannick Allanore, G. Riemekasten, D. Martinovic Kaliterna, Daniel E. Furst, Celia J. F. Lin, Dinesh Khanna, Oliver Distler, J. Goldin
Publikováno v:
B15. IMMUNOTHERAPY FOR LUNG DISEASE.
Autor:
Christopher P. Denton, Dinesh Khanna, Daniel E. Furst, Jeffrey Siegel, Helen Spotswood, Celia J. F. Lin
Publikováno v:
Annals of the Rheumatic Diseases. 79:394.1-394
Background:The anti–interleukin-6 (IL-6) receptor-α antibody tocilizumab (TCZ) demonstrated skin score improvement and forced vital capacity (FVC) preservation in patients with systemic sclerosis (SSc) in a phase 2 randomized controlled trial.1,2D
Autor:
Martin Aringer, Robert Spiera, Bhaskar Dasgupta, Daniel Engelbert Blockmans, Min Bao, Elisabeth Brouwer, M. C. Cid, Sebastian Unizony, Carlo Salvarani, Helen Spotswood, John H. Stone, Jürgen Rech
Publikováno v:
Annals of the Rheumatic Diseases. 79:20.1-20
Background:In part 1 of the 52-week, double-blind GiACTA trial, tocilizumab (TCZ) every week (QW) or every other week (Q2W) + prednisone tapering reduced the risk for flare versus placebo (PBO) + 26-week prednisone tapering among patients with new-on
Autor:
Tracy M. Frech, Lorinda Chung, Janet E. Pope, Jeffrey Siegel, Helen Spotswood, Laura Burke, Ulf Müller-Ladner, Dinesh Khanna, Santhanam Lakshminarayanan, Gabriela Riemekasten, Jacob M van Laar, Virginia D. Steen, Christopher P. Denton, Yannick Allanore, Gerhard Fierlbeck, Daniel E. Furst, Murray Baron, Michael B. Arnold, Angelika Jahreis, Marina E Anderson
Publikováno v:
Rheumatology (Oxford, England). 57(1)
OBJECTIVES: Patient acceptable symptom state (PASS) as an absolute state of well-being has shown promise as an outcome measure in many rheumatologic conditions. We aimed to assess whether PASS may be effective in active diffuse cutaneous SSc differen
Autor:
Dinesh Khanna, Gerhard Fierlbeck, Yannick Allanore, Thierry Sornasse, Jacob M van Laar, Robert Lafyatis, Tracy M. Frech, Helen Spotswood, Santhanam Lakshminarayanan, Alyssa Morimoto, Ulf Müller-Ladner, Sebastian Dziadek, Angelika Jahreis, Christopher P. Denton, Janet E. Pope, Marina E Anderson, Gabriela Riemekasten, Jeffrey Siegel, Virginia D. Steen, Murray Baron, Daniel E. Furst, Giuseppina Stifano, Lorinda Chung, Haiyin Chen-Harris
Publikováno v:
The Lancet
LANCET
The Lancet, 387(10038), 2630. Elsevier Limited
LANCET
The Lancet, 387(10038), 2630. Elsevier Limited
Summary Background Systemic sclerosis is a rare disabling autoimmune disease with few treatment options. The efficacy and safety of tocilizumab, an interleukin 6 receptor-α inhibitor, was assessed in the faSScinate phase 2 trial in patients with sys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aca4633735858ab446c6f078549dbc7